These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 27040854)
21. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336 [TBL] [Abstract][Full Text] [Related]
22. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821 [TBL] [Abstract][Full Text] [Related]
23. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743 [TBL] [Abstract][Full Text] [Related]
24. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121 [TBL] [Abstract][Full Text] [Related]
25. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266 [TBL] [Abstract][Full Text] [Related]
26. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634 [TBL] [Abstract][Full Text] [Related]
27. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037 [TBL] [Abstract][Full Text] [Related]
28. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R; JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014 [TBL] [Abstract][Full Text] [Related]
29. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience. Sauter JL; Butnor KJ Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394 [TBL] [Abstract][Full Text] [Related]
30. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855 [TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer. Sun HB; Ou W; Li Y; Fang Q; Qin J; Zhang L; Wang SY Clin Lung Cancer; 2013 Jul; 14(4):376-82. PubMed ID: 23291256 [TBL] [Abstract][Full Text] [Related]
32. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793 [TBL] [Abstract][Full Text] [Related]
33. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer? Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011 [TBL] [Abstract][Full Text] [Related]
34. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Chang YL; Wu CT; Shih JY; Lee YC Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490 [TBL] [Abstract][Full Text] [Related]
35. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Al-Kuraya K; Siraj AK; Bavi P; Al-Jommah N; Ezzat A; Sheikh S; Amr S; Al-Dayel F; Simon R; Guido S Hum Pathol; 2006 Apr; 37(4):453-7. PubMed ID: 16564920 [TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients. Mäki-Nevala S; Rönty M; Morel M; Gomez M; Dawson Z; Sarhadi VK; Telaranta-Keerie A; Knuuttila A; Knuutila S J Thorac Oncol; 2014 Jun; 9(6):886-91. PubMed ID: 24828666 [TBL] [Abstract][Full Text] [Related]
37. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828 [TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769 [TBL] [Abstract][Full Text] [Related]